HCW Biologics Inc. — Form 8-K Summary
Reporting date: June 13, 2023, with the report filed June 14, 2023. The filing reports the results of the company’s 2023 Annual Meeting of Stockholders under Item 5.07.
Business Context and Reporting Period
HCW Biologics Inc. is a Delaware-incorporated biotechnology company headquartered in Miramar, Florida. Its common stock trades on Nasdaq under the symbol HCWB. The company is designated as an emerging growth company.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Material Changes Versus the Prior Comparable Period
The filing does not report financial or operating changes versus a prior comparable period. It reports annual meeting voting outcomes only.
Annual Meeting Results, Outlook, and Risks
- Director elections: Lisa M. Giles was elected as a Class II director with 18,867,295 votes for, 503,344 withheld, and 2,228,627 broker non-votes. Rick S. Greene was elected with 18,857,446 votes for, 513,193 withheld, and 2,228,627 broker non-votes.
- Each elected director will serve a three-year term expiring at the 2026 Annual Meeting, subject to earlier death, resignation, disqualification, removal, or replacement.
- Auditor ratification: Stockholders ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 21,550,829 votes for, 3,374 against, and 45,063 abstentions.
- The filing provides no new guidance, management outlook, contingencies, risk updates, or unusual financial items.
Investor Verification Items
- Confirm the tenure and committee assignments of directors Giles and Greene in subsequent proxy or governance disclosures.
- Review future filings for Grant Thornton LLP’s audit conclusions and any reported accounting or internal-control matters.
- Use the company’s periodic reports, rather than this 8-K, to verify financial performance, liquidity, debt, cash runway, and operating outlook.